Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
New methods for spatial transcriptomic profiling include a sequential FISH-based method and one that makes use of DNA-barcoded bead arrays.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
Some of the mutational signatures the researchers observed were similar to ones previously seen in B cell tumors, underscoring the link between aging and cancer.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
LabCorp's Covance business plans to offer single-cell services on Mission Bio's platform to pharma and to explore its use in companion diagnostics.
The effort, outlined in a Development Cell paper published online today, aims to complement the ongoing Human Cell Atlas initiative, but with a focus on pediatric health.
The startup's technology, which it plans to launch through an early-access program this summer, is based on a cell fixing and combinatorial barcoding strategy.
Speakers at this year's ABRF meeting described how they used single-cell tools in combination with other single-cell approaches and other methods.
A new analysis founds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.